Cognition Therapeutics (CGTX) Preferred Stock Liabilities (2020 - 2021)
Cognition Therapeutics (CGTX) reported Preferred Stock Liabilities of $5.4 million for Q3 2021, up 16.94% year-over-year from $4.6 million in Q3 2020, and down 81.63% on a QoQ basis from $29.4 million in Q2 2021.
Cognition Therapeutics (CGTX) has 2 years of Preferred Stock Liabilities data on file, last reported at $5.4 million in Q3 2021.
- Quarterly Preferred Stock Liabilities rose 16.94% year-over-year to $5.4 million in Q3 2021, while the trailing twelve-month figure through Sep 2021 was $5.4 million (up 16.94% YoY) and the FY2020 annual result came in at $55.4 million, changed N/A from the prior year.
- Preferred Stock Liabilities retreated to $5.4 million in Q3 2021 per CGTX's latest filing, from $29.4 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $55.4 million in Q4 2020 and bottomed at $4.6 million in Q3 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - | - |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | - |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,282.79 Bn | 2,282.72 Bn | - | - |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn | - |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn | - |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn | - |
| 10 | Cognition Therapeutics | 648,270.00 | 648,270.00 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 5.40 Mn |
| Jun 30, 2021 | 29.39 Mn |
| Mar 31, 2021 | 4.62 Mn |
| Dec 31, 2020 | 55.37 Mn |
| Sep 30, 2020 | 4.62 Mn |